The Horizon 2020 project GLINT aims to develop a potentially disruptive new diagnostic tool and a set of technologies for cancer imaging which will allow for earlier, more accurate and more reliable cancer diagnosis.
Cancer is one of the most devastating diseases the world is currently facing. It is usually detected through advanced medical imaging, and early detection remains a decisive factor for increasing the chances of survival and the potential for full recovery.
The GLINT project addresses the current global lack of safe, cheap, easily accessible and accurate image-based metabolic evaluation techniques to detect cancer and will develop an innovative diagnostic tool and a set of technologies for in vivo cancer imaging which can characterise and image glucose delivery, uptake and metabolism in cancer. Once the GLINT project is successful, patients will be able to benefit from a non-invasive, radiation-free method for cancer assessment.
The GLINT project aims to develop and bring to the clinic a potentially disruptive new diagnostic tool and a set of technologies for in vivo cancer imaging which can characterise and image glucose delivery, uptake and metabolism in cancer. It addresses the current global lack of safe, cheap, easily accessible and accurate image-based metabolic evaluation techniques to detect cancer and will develop an innovative method which will allow for more accurate, less invasive, more reliable and earlier cancer diagnosis.
GLINT involves six interdependent scientific (WP2-7) and two horizontal work packages (WP1&8). Each work package contains tasks and deliverables vital to the project's success.
The GLINT consortium is made up of a multidisciplinary team of eight partners from leading research institutions and industry from in- and outside the European Union: Austria, France, Germany, Italy, Israel, Switzerland, and the United Kingdom. Find out more about our partners by clicking on the flags on the map and the partner logos on the right.
GLINT will bring to the clinics a groundbreaking new technology which allows for more accurate, more reliable and earlier cancer diagnosis.
Get access to our list of scientific peer reviewed papers and publications by the GLINT researchers relating to the project’s research results and take a look at all dissemination material of the GLINT project, such as flyers, brochures, fact sheets, and articles published in the popular press.
Download all our promotional materials, such as flyers and folders, and read our press releases.
If you have any questions about the GLINT project, please do not hesitate to contact us by using the message form below
Xavier Golay is professor of MR Neurophysics and Translational Neuroscience at the UCL Institute of Neurology. As the original inventor of the GlucoCEST method and as GLINT Scientific Coordinator, he is leading the project in scientific aspects.
Katharina Krischak is a project manager at the European Institute for Biomedical Imaging Research and is responsible for the day-to-day management of the GLINT project.
Natalie Nestorowicz is a project manager at UCL’s European Research and Innovation Office and responsible for the management of contractual and financial matters for GLINT.
GLINT
This project has received funding from the European Union‘s Horizon 2020 research and innovation programme under grant agreement No 667510.
Copyright GLINT 2016
